[Vcanbio: wholly-owned subsidiary obtains notice of approval of Drug Clinical trial] Vcanbio announced that Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary, received two "Drug Clinical trial approval notices" approved and issued by the State Drug Administration on VUM02 injection. VUM02 injection is intended to be used in patients with chronic plus acute (subacute) liver failure and moderate and severe acute respiratory distress syndrome.